Literature DB >> 4013993

Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing.

R F Poser, P J Podrid, F Lombardi, B Lown.   

Abstract

There is evidence that antiarrhythmic drugs can worsen ventricular arrhythmias in patients. In a previous study ventricular arrhythmias worsened 11% when noninvasive monitoring and exercise tests were performed to evaluate drug effect. How frequently this complication occurs when patients undergo electrophysiologic studies is not known. Electrophysiologic (EP) tests were carried out in 63 patients who had a history of malignant, sustained ventricular tachyarrhythmias. Monitoring and exercise tests showed low-frequency or nonreproducible ventricular arrhythmia. Criteria for definite drug-induced aggravation of arrhythmia included conversion of nonsustained ventricular tachycardia to a sustained ventricular arrhythmia and provocation of the end point with one extrastimulus when three were required during control. Aggravation was deemed possible when, as compared to a control group, the end point resulted with the use of one less extrastimulus and sustained tachycardia with a more rapid rate was provoked. A total of 216 single drug studies were performed (3.4/patient). In general, definite or possible aggravation occurred in 35 tests (16%). In 28 cases (12.9%) aggravation was categorized as definite, while in 7 cases (3.2%) the induced arrhythmia was deemed as possibly related to the use of the antiarrhythmic drugs. Drug tests with multiple agents caused aggravation of arrhythmia in 19 patients (30%). Therefore, exacerbation of arrhythmia by antiarrhythmic drugs also occurs during electrophysiologic study. The incidence approximates that reported when monitoring and exercise tests are used for evaluating drug efficacy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4013993     DOI: 10.1016/0002-8703(85)90507-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

1.  Electrophysiologic evaluation of antiarrhythmic drugs.

Authors:  P Touboul
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Effect of ajmaline on sustained ventricular tachycardia induced by programmed electrical stimulation in conscious dogs after myocardial infarction.

Authors:  H Todt; G Krumpl; N Zojer; K Krejcy; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

3.  Electrophysiological testing after acute myocardial infarction.

Authors:  S M Cobbe
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-17

4.  Management of arrhythmias.

Authors:  C E Rotem
Journal:  Can Fam Physician       Date:  1987-11       Impact factor: 3.275

Review 5.  Proarrhythmia, a serious complication of antiarrhythmic drugs.

Authors:  P J Podrid
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

6.  Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events.

Authors:  B Brembilla-Perrot; L Jacquemin; A Terrier de la Chaise; D Beurrier
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

7.  Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens.

Authors:  B Brembilla-Perrot; E Aliot; J Clementy; P Cosnay; P Djiane; J P Fauchier; S Kacet; D Lellouche; P Mabo; M Richard
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

8.  H2-receptor antagonism is not pro-arrhythmic in a chronic canine model.

Authors:  A C Uprichard; D W Harron
Journal:  Basic Res Cardiol       Date:  1990 Sep-Oct       Impact factor: 17.165

Review 9.  Antiarrhythmic drug treatment: need for continuous vigilance.

Authors:  H J Wellens; J L Smeets; M Vos; A P Gorgels
Journal:  Br Heart J       Date:  1992-01

Review 10.  Cardiac electrophysiology and conduction pathway ablation.

Authors:  J Renwick; C Kerr; R McTaggart; J Yeung
Journal:  Can J Anaesth       Date:  1993-11       Impact factor: 5.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.